<div id="readability-page-1"><p>Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) CFO Frank Stokes sold 7,000 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $27.44, for a total transaction of $192,080.00. Following the sale, the chief financial officer directly owned 52,483 shares of the company's stock, valued at $1,440,133.52. This represents a 11.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.</p><div><p><span></span><span>Get <strong>Castle Biosciences</strong> alerts:</span></p></div><h2>Castle Biosciences Stock Down 0.9%</h2><p>NASDAQ CSTL traded down $0.26 on Thursday, reaching $27.91. 419,929 shares of the stock traded hands, compared to its average volume of 445,124. The company has a market cap of $829.76 million, a price-to-earnings ratio of -32.84 and a beta of 1.09. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.11 and a current ratio of 5.26. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28. The company has a fifty day moving average price of $36.41 and a 200-day moving average price of $31.38. </p><p>Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.15. The company had revenue of $81.88 million during the quarter, compared to analyst estimates of $81.19 million. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%.  As a group, research analysts forecast that  Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year. </p><h2>Institutional Trading of Castle Biosciences</h2><p>Several hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd grew its stake in  Castle Biosciences by 188.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,099 shares of the company's stock worth $82,000 after buying an additional 1,371 shares during the last quarter.  Invesco Ltd. raised its stake in  Castle Biosciences by 142.6% in the fourth quarter. Invesco Ltd. now owns 135,461 shares of the company's stock valued at $5,269,000 after buying an additional 79,621 shares during the last quarter.  Mackenzie Financial Corp boosted its holdings in  Castle Biosciences by 54.2% in the fourth quarter. Mackenzie Financial Corp now owns 37,317 shares of the company's stock worth $1,464,000 after acquiring an additional 13,113 shares in the last quarter.  Empowered Funds LLC boosted its holdings in  Castle Biosciences by 24.2% in the fourth quarter. Empowered Funds LLC now owns 121,920 shares of the company's stock worth $4,743,000 after acquiring an additional 23,740 shares in the last quarter.  Finally, XTX Topco Ltd purchased a new stake in shares of  Castle Biosciences during the fourth quarter worth about $861,000. Hedge funds and other institutional investors own  92.60% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities analysts recently commented on the stock. BTIG Research boosted their price objective on shares of Castle Biosciences from $38.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, December 12th. Robert W. Baird lifted their price target on Castle Biosciences from $41.00 to $44.00 and gave the company an &#34;outperform&#34; rating in a report on Friday, February 27th. Morgan Stanley upgraded Castle Biosciences to a &#34;buy&#34; rating in a research note on Monday. Canaccord Genuity Group raised their price objective on Castle Biosciences from $37.00 to $50.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, December 22nd. Finally, Weiss Ratings  reiterated a &#34;sell (d)&#34; rating on shares of Castle Biosciences in a research note on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $47.57.</p><p><b>Read Our Latest Research Report on CSTL</b></p><h2>About Castle Biosciences</h2> (Get Free Report)<p>Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.  </p><p>The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.</p><h2>See Also</h2><ul><li>Five stocks we like better than Castle Biosciences</li><li>The gold chart Wall Street is terrified of…</li><li>America’s 1776 happening again</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>Unlocked: Elon Musk’s Next Big IPO</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1NUTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1NUTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Castle Biosciences Right Now?</h2><p>Before you consider Castle Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.</p><p>While Castle Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IBBQ

ARKG

<p>Castle Biosciences CFO Frank Stokes sold 7,000 shares of the company's stock at an average price of $27.44, totaling $192,080. Following the sale, he owns 52,483 shares, reflecting an 11.77% decrease in his position. The transaction was disclosed to the SEC. Castle Biosciences' stock recently traded down 0.9% to $27.91, with a market cap of $829.76 million. Analysts have a consensus rating of "Moderate Buy" with an average target price of $47.57.</p>

Frank Stokes Sells 7,000 Shares of Castle Biosciences (NASDAQ:CSTL) Stock